Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Do | Roche's Genentech enters $765m autoimmune disease partnership with Repertoire | ||
Do | Biogen's Skyclarys granted MHRA approval for rare movement disorder Friedreich's ataxia | ||
Do | Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer | ||
Do | DE&I - don't throw the baby out with the bathwater | ||
Mi | Pfizer's Hympavzi granted MHRA approval to treat haemophilia A and B | ||
Mi | BMS receives NICE recommendation for immunotherapy combination in colorectal cancer | ||
Mi | AstraZeneca/Daiichi Sankyo's Enhertu shows promise in first-line HER2-positive breast cancer | ||
Mi | Tackling the antibiotic resistance crisis | ||
Di | Unlock the Future of Patient Recruitment: Learnings from 15 Years of Innovation | ||
Di | Sanofi/Regeneron's Dupixent granted FDA approval for chronic spontaneous urticaria | ||
Di | GSK's Blenrep combinations approved by MHRA to treat multiple myeloma | ||
Di | FDA approves pre-filled syringe version of argenx's immune disorder drug Vyvgart | ||
Di | Coach Tolstoy: The surprising coaching lesson from Russian literature | ||
17.04. | GSK's five-in-one meningococcal vaccine recommended by CDC advisory committee | ||
17.04. | LEO Pharma and the Parker Institute join forces to advance dermatology research | ||
17.04. | FDA grants interchangeable designation to Celltrion's Humira biosimilar Yuflyma | ||
17.04. | The impact of multiple sclerosis on ageing patients | ||
16.04. | Shared decision-making in oncology - turning principles into practice | ||
16.04. | Biogen/Eisai's Alzheimer's disease drug Leqembi granted EC approval | ||
16.04. | Merck and Cyprumed enter oral peptide partnership worth over $493m | ||
16.04. | Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m | ||
16.04. | Reducing disparities in healthcare through shared decision-making | ||
15.04. | NHS programme to give melanoma patients fast-track access to skin cancer vaccine | ||
15.04. | J&J's subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma | ||
15.04. | Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer |